- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07228104
Uso de inyecciones de esteroides para prevenir la recurrencia de la estenosis traqueal en la estenosis subglótica idiopática (ASTRO)
Resultados de Esteroides Adyuvantes en la Estenosis Subglótica Idiopática
This study will examine the ability of steroid injections into the site of stenosis following surgical dilation to delay the need for repeated surgical dilations.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Alexander Hillel, M.D.
- Número de teléfono: 4432876006
- Correo electrónico: ahillel@jh.edu
Ubicaciones de estudio
-
-
California
-
San Diego, California, Estados Unidos, 92121
- Aún no reclutando
- University of California - San Diego
-
Contacto:
- Daniel Cates
- Correo electrónico: djcates@health.ucsd.edu
-
Investigador principal:
- Daniel Cates, MD
-
San Francisco, California, Estados Unidos, 94115
- Aún no reclutando
- University of California - San Francisco
-
Investigador principal:
- Clark Rosen, MD
-
Contacto:
- Meera Kohli
- Correo electrónico: meera.kohli@ucsf.edu
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Aún no reclutando
- University of Colorado
-
Contacto:
- Yosr Doghri
- Correo electrónico: yosr.doghri@cuanschutz.edu
-
Investigador principal:
- Matthew Clary, MD
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- University of South Florida
-
Contacto:
- Jacquie Persaud
- Correo electrónico: jdpersaud@usf.edu
-
Investigador principal:
- Yael Bensoussan, MD
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Hospitals and Clinics
-
Contacto:
- Emma Thayer
- Correo electrónico: emma-thayer@uiowa.edu
-
Investigador principal:
- Matthew Hoffman, MD, PhD
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21231
- Reclutamiento
- Johns Hopkins Hospital
-
Investigador principal:
- Alexander Hillel, MD
-
Contacto:
- Sarah E Collins, M.S.
- Número de teléfono: 434-962-3058
- Correo electrónico: shirsh1@jh.edu
-
Contacto:
- Sam L Collins, Ph.D.
- Número de teléfono: 4107020420
- Correo electrónico: scollin7@jhmi.edu
-
Sub-Investigador:
- Kevin Motz, MD
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester Medical Center
-
Contacto:
- Paul Allen
- Correo electrónico: paul_allen@urmc.rochester.edu
-
Investigador principal:
- G. Todd Schneider, MD, MS
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University Medical Center
-
Investigador principal:
- Alexander Gelbard, MD
-
Contacto:
- Samantha Salvi Cruz
- Correo electrónico: samantha.salvicruz@vumc.org
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Reclutamiento
- University of Utah
-
Contacto:
- Chen Wilson
- Correo electrónico: u0661901@utah.edu
-
Investigador principal:
- Breanne Schiffer, MD, MPH
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Aún no reclutando
- University of Wisconsin - Madison
-
Contacto:
- Maddie Baranek
- Correo electrónico: baranek@surgery.wisc.edu
-
Investigador principal:
- David Francis, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnosis of iSGS following the NoAAC criteria which involves ruling out known causes for airway stenosis. Participants may be newly diagnosed or carry an existing diagnosis of iSGS;
- Age Range: 18 years to 80 years old at the time of consent;
- Sex distribution: all eligible men and women will be included, and no one will be excluded;
- Have a life expectancy of ≥6 months; and,
- ECOG performance status of 0 or 1.
Exclusion Criteria:
-
History of subglottic stenosis from identifiable cause (not idiopathic), including any of the below clinical criteria:
- Prolonged endotracheal intubation or tracheostomy (intervention greater than 7 days immediately prior to diagnosis of subglottic stenosis);
- External physical trauma (including but not limited to blunt, penetration, chemical, or thermal injury) that causes injury to the subglottis;
- Clinical diagnosis of granulomatosis with polyangiitis (GPA);
- Radiation exposure to the neck;
- Complications resulting from the Index Procedure, including needing an endotracheal tube or tracheostomy immediately following surgery or a perforation of the trachea;
-
Current or previous treatment with SILSI;
-
Use of systemic corticosteroids (oral, intravenous, or intramuscular glucocorticoids), regardless of indication, within 7 days before triamcinolone administration;
- Local administration of corticosteroids (ophthalmic, intranasal, inhaled) is not prohibited. However, the administration of intraarticular corticosteroids during the Study Drug Dosing phase is not recommended due to potential increased risk of infection.
- Intralesional administration, in a site other than the subglottis, of corticosteroids should be discussed with the site PI before enrollment.
- Use of inhaled steroids is permitted during the study if the participant was taking at the time of consent, and no new inhaled steroids can be started while enrolled in the study.
-
Intraarticular corticosteroids during the Study Drug Dosing phase due to potential increased risk of infection;
-
Use of anticoagulants other than aspirin (daily aspirin dose should not exceed 81mg);
-
Pulmonary disease including interstitial lung disease or COPD/emphysema;
-
Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within 21 days of Enrollment;
-
Poorly controlled diabetes as defined by a HbA1C value greater or equal to 8.0 in the last 180 days;
-
Participants with active cancer or a history of cancer in the last 5 years prior to enrollment, except for squamous or basal cell carcinoma of the skin;
-
Participation in any clinical trial involving an investigational drug or device, within four weeks, or 5 half-lives of the investigational agent (whichever time point is longer) prior to enrollment or during this trial participation;
-
Active autoimmune disease requiring systemic treatment;
-
History of solid organ transplant due to use of immunosuppression;
-
Contraindication to any aspect of the index procedure;
-
Inability to tolerate in-office SILSI procedure;
-
Contraindication, hypersensitivity, or history of intolerance to oral or injectable steroids;
-
Contraindication to SMOFlipid including any of the below:
- Severe lipid metabolism disorders characterized by hypertriglyceridemia (greater than 500 mg/dL);
- Hypersensitivity to eggs, soybean, peanut protein, or any active ingredient in SMOFlipid;
- History of intolerance to SMOFlipid;
-
Participants with known, suspected, or plan for becoming pregnant in the next 6 months after the index procedure, or participants who are breastfeeding;
-
NYHA class II-IV heart failure within the past 6 months prior to Enrollment;
-
History of angioedema;
-
Lack of capacity to consent;
-
Alcohol or substance abuse or dependence in the past 6 months prior to Enrollment;
-
Participants who for any reason may not complete the study as judged by the PI;
-
Participants planning to move to another city or state for 6 months after the Index Procedure;
-
Not able to undergo phlebotomy as reported by the participant or determined by the study coordinator or physician.
-
The presence of a medical condition, lab test result, and/or use of a medication and/or any substance, individually or in aggregate, that in the judgement of the site investigator could impair study participation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Inyección intralesional de esteroides con Triamcinolona
|
Intralesional Triamcinolone injection 3x at one, two, and three months following surgical dilation |
|
Comparador de placebos: Inyección intralesional de placebo
|
Intralesional Placebo injection 3x at one, two, and three months following surgical dilation |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Cambio en el Flujo Espiratorio Máximo (Litros/min)
Periodo de tiempo: 6 Meses
|
6 Meses
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical COPD Questionnaire
Periodo de tiempo: 6 months
|
Score range 0-60, Lower score indicates better health |
6 months
|
|
Voice Handicap Index-10
Periodo de tiempo: 6 Months
|
Score range 0 to 40, Lower score indicates better voice |
6 Months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Alexander Hillel, MD, Johns Hopkins University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB00507375
- 1UG3HL173394-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .